Fennec Pharmaceuticals Inc.

6.27-0.1600-2.49%Vol 88.98K1Y Perf -8.35%
Apr 16th, 2021 16:00 DELAYED
BID6.28 ASK6.29
Open6.51 Previous Close6.43
Pre-Market- After-Market-
 - -  - -%
Target Price
13.00 
Analyst Rating
Strong Buy 1.00
Potential %
107.34 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap163.04M 
Earnings Rating
Strong Buy
Price Range Ratio 52W %
25.04 
Earnings Date
13th May 2021

Today's Price Range

6.146.54

52W Range

4.8010.67

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-0.16%
1 Month
-16.18%
3 Months
-15.61%
6 Months
-17.72%
1 Year
-8.35%
3 Years
-53.76%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
FENC6.27-0.1600-2.49
AAPL134.16-0.3400-0.25
GOOG2 297.761.10000.05
MSFT260.741.24000.48
XOM56.66-0.3200-0.56
WFC43.841.60003.79
JNJ162.241.85001.15
FB306.18-1.6400-0.53
GE13.39-0.1600-1.18
JPM153.301.13000.74
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.19-0.1331.58
Q03 2020-0.18-0.24-33.33
Q02 2020-0.19-0.21-10.53
Q01 2020-0.19-0.190.00
Q04 2019-0.13-0.18-38.46
Q03 2019-0.24-0.0962.50
Q02 2019-0.14-0.24-71.43
Q01 2019-0.15-0.1313.33
Earnings Per EndEstimateRevision %Trend
3/2021 QR0.00100.00Positive
6/2021 QR0.03400.00Positive
12/2021 FY1.140.88Positive
12/2022 FY0.307.14Positive
Next Report Date13th May 2021
Estimated EPS Next Report-0.12
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume88.98K
Shares Outstanding26.00M
Trades Count633
Dollar Volume585.99K
Avg. Volume100.53K
Avg. Weekly Volume86.13K
Avg. Monthly Volume166.16K
Avg. Quarterly Volume103.60K

Fennec Pharmaceuticals Inc. (NASDAQ: FENC) stock closed at 6.27 per share at the end of the most recent trading day (a -2.49% change compared to the prior day closing price) with a volume of 89.64K shares and market capitalization of 163.04M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 4 people. Fennec Pharmaceuticals Inc. CEO is Rostislav Raykov.

The one-year performance of Fennec Pharmaceuticals Inc. stock is -8.35%, while year-to-date (YTD) performance is -15.84%. FENC stock has a five-year performance of %. Its 52-week range is between 4.8 and 10.67, which gives FENC stock a 52-week price range ratio of 25.04%

Fennec Pharmaceuticals Inc. currently has a PE ratio of -, a price-to-book (PB) ratio of 12.42, a price-to-sale (PS) ratio of 915.48, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -77.36%, a ROC of -80.03% and a ROE of -86.24%. The company’s profit margin is -%, its EBITDA margin is -1 968.20%, and its revenue ttm is $172.26 Thousand , which makes it $0.01 revenue per share.

Of the last four earnings reports from Fennec Pharmaceuticals Inc., there were 1 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.12 for the next earnings report. Fennec Pharmaceuticals Inc.’s next earnings report date is 13th May 2021.

The consensus rating of Wall Street analysts for Fennec Pharmaceuticals Inc. is Strong Buy (1), with a target price of $13, which is +107.34% compared to the current price. The earnings rating for Fennec Pharmaceuticals Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Fennec Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Fennec Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 10.78, ATR14 : 0.45, CCI20 : -42.41, Chaikin Money Flow : 0.17, MACD : -0.39, Money Flow Index : 60.95, ROC : -2.79, RSI : 46.24, STOCH (14,3) : 34.58, STOCH RSI : 0.54, UO : 54.51, Williams %R : -65.42), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Fennec Pharmaceuticals Inc. in the last 12-months were: Robert Andrade (Option Excercise at a value of $599 328), Rostislav Raykov (Option Excercise at a value of $599 328)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (100.00 %)
2 (100.00 %)
2 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Fennec Pharmaceuticals Inc.

Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is primarily engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its lead product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children.

CEO: Rostislav Raykov

Telephone: +1 919 636-4530

Address: 68 TW Alexander Drive, Research Triangle Park 27709, NC, US

Number of employees: 4

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

60%40%

Bearish Bullish

52%48%

Bearish Bullish

63%38%

News

Stocktwits